Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an announcement.
Cardiol Therapeutics has filed its Form 6-K for May 2026, furnishing unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three months ended March 31, 2026, along with CEO and CFO certification filings. As of quarter-end, the company reported total assets of $31.4 million, including $27.7 million in cash and cash equivalents, total liabilities of $7.2 million, and equity of $24.2 million, highlighting a strengthened balance sheet versus December 31, 2025.
For the first quarter of 2026, Cardiol posted a net loss of $10.8 million, widening from a $8.3 million loss a year earlier as research and development expenses increased to $4.9 million and general and administrative costs remained elevated at $4.8 million. Despite higher operating losses and a larger derivative liability, the company’s cash position improved, supported by higher share capital and warrant values, factors that are likely to be closely watched by investors assessing Cardiol’s funding runway and ongoing development programs.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing therapies in the cardiovascular and inflammatory disease space. The company is listed in the United States as a foreign private issuer and prepares its financial statements in Canadian dollars, reflecting its cross-border capital markets presence.
YTD Price Performance: 37.40%
Average Trading Volume: 135,935
Technical Sentiment Signal: Buy
Current Market Cap: C$201.4M
See more data about CRDL stock on TipRanks’ Stock Analysis page.